Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2017										Related Pages
										Return to Main Menu
Table 8. Tuberculosis Cases and Percentages, by Resistance to Isoniazid (INH)1, Origin of Birth, and Previous History of TB: United States, 1993–2017
Table 8. Tuberculosis Cases and Percentages, by Resistance to Isoniazid (INH), Origin of Birth, and Previous History of TB: United States, 1993–2017
Year
All INH-Resistant2
Isoniazid Resistant TB CasesTotal INH-Resistant
U.S.-Born INH-Resistant3
Non-U.S.–Born3,4 INH-ResistantPrevious TB
No previous TB
Previous TB
No previous TB
Previous TB
No previous TBEligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)1993
1,534
982
161
(16.4)
16,601
1,367
(8.2)
668
83
(12.4)
11,808
789
(6.7)
301
75
(24.9)
4,665
564
(12.1)1994
1,543
1033
175
(16.9)
16,417
1,352
(8.2)
693
81
(11.7)
11,009
708
(6.4)
336
93
(27.7)
5,291
632
(11.9)1995
1,351
958
168
(17.5)
16,023
1,173
(7.3)
592
77
(13.0)
10,340
554
(5.4)
364
91
(25.0)
5,652
618
(10.9)1996
1,284
862
142
(16.5)
15,360
1,133
(7.4)
559
68
(12.2)
9,637
495
(5.1)
303
74
(24.4)
5,676
637
(11.2)1997
1,195
742
109
(14.7)
14,449
1,078
(7.5)
455
35
(7.7)
8,696
435
(5.0)
286
74
(25.9)
5,708
640
(11.2)1998
1,120
749
98
(13.1)
13,420
1,011
(7.5)
485
38
(7.8)
7,695
366
(4.8)
262
60
(22.9)
5,692
643
(11.3)1999
1,000
669
82
(12.3)
12,659
900
(7.1)
382
25
(6.5)
7,011
284
(4.1)
284
55
(19.4)
5,596
614
(11.0)2000
981
632
84
(13.3)
11,829
889
(7.5)
360
22
(6.1)
6,141
269
(4.4)
272
62
(22.8)
5,659
617
(10.9)2001
897
629
87
(13.8)
11,514
800
(6.9)
324
28
(8.6)
5,570
241
(4.3)
302
59
(19.5)
5,908
558
(9.4)2002
912
570
80
(14.0)
10,820
826
(7.6)
303
23
(7.6)
5,059
206
(4.1)
265
57
(21.5)
5,720
619
(10.8)2003
904
524
65
(12.4)
10,752
823
(7.7)
253
16
(6.3)
4,853
213
(4.4)
271
49
(18.1)
5,869
606
(10.3)2004
872
537
64
(11.9)
10,482
801
(7.6)
274
15
(5.5)
4,683
214
(4.6)
263
49
(18.6)
5,789
587
(10.1)2005
842
507
70
(13.8)
10,065
761
(7.6)
240
18
(7.5)
4,396
188
(4.3)
267
52
(19.5)
5,652
567
(10.0)2006
845
493
67
(13.6)
9,907
770
(7.8)
203
9
(4.4)
4,126
173
(4.2)
289
57
(19.7)
5,765
596
(10.3)2007
798
496
71
(14.3)
9,646
715
(7.4)
206
14
(6.8)
3,837
163
(4.2)
288
57
(19.8)
5,755
548
(9.5)2008
836
429
57
(13.3)
9,306
775
(8.3)
170
13
(7.6)
3,647
189
(5.2)
259
44
(17.0)
5,653
585
(10.3)2009
763
341
52
(15.2)
7,739
651
(8.4)
115
6
(5.2)
3,014
187
(6.2)
225
46
(20.4)
4,717
464
(9.8)2010
693
359
63
(17.5)
7,769
621
(8.0)
131
13
(9.9)
2,931
164
(5.6)
228
50
(21.9)
4,832
457
(9.5)2011
754
345
59
(17.1)
7,554
688
(9.1)
137
9
(6.6)
2,702
173
(6.4)
208
50
(24.0)
4,849
515
(10.6)2012
692
356
55
(15.4)
7,083
637
(9.0)
127
8
(6.3)
2,523
151
(6.0)
229
47
(20.5)
4,560
486
(10.7)2013
675
301
48
(15.9)
6,866
622
(9.1)
98
8
(8.2)
2,286
131
(5.7)
203
40
(19.7)
4,575
491
(10.7)2014
691
336
63
(18.8)
6,746
624
(9.2)
95
5
(5.3)
2,187
164
(7.5)
241
58
(24.1)
4,555
460
(10.1)2015
683
317
51
(16.1)
6,961
631
(9.1)
100
7
(7.0)
2,194
149
(6.8)
217
44
(20.3)
4,762
481
(10.1)2016
650
300
56
(18.7)
6,687
590
(8.8)
82
6
(7.3)
2,048
124
(6.1)
218
50
(22.9)
4,632
466
(10.1)2017
608
267
53
(19.9)
6,216
545
(8.8)
53
2
(3.8)
1,744
95
(5.4)
214
51
(23.8)
4,462
449
(10.1)1Resistance to at least isoniazid. Isolates may be resistant to other drugs. Excludes cases with susceptibility testing not done or unknown for isoniazid. Cases have been susceptibility tested to at least isoniazid and rifampin.2This column provides an overall total of all INH-resistant cases, including those where previous history of TB is unknown and origin or birth is unknown.3Excludes cases where previous history of TB is unknown and cases where origin of birth is unknown.4Includes persons born outside the United States (including the U.S. territories).**Note:** Data for all years updated through June 1, 2018.
							
					
						Page last reviewed:  October 22, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue